ArticleCureus2025
The Role of HbA1c in the Follow-Up and Control of Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.Diabetes, obesity & metabolism · 2025Trial
- Review
- Selected Emerging Biomarkers in Type 2 Diabetes Mellitus: Clinical Insights and Implications for Precision Care.Medicina (Kaunas, Lithuania) · 2026Review
- Prevalence and associated risk factors of Pseudomonas aeruginosa infection in Diabetic wounds in Duhok province, Iraq.PloS one · 2026Article
- Seasonal Variations in Estimated Whole Blood Viscosity Associated with HbA1c: Evidence from Retrospective Pathology Review for Diabetes Management.International journal of molecular sciences · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction HbA1c is a biomarker that plays an essential role in the diagnosis and follow-up of diabetic patients. The sensitivity and specificity of the biomarker may be affected by common comorbidities seen in individuals with diabetes mellitus, such as kidney affection, cardiac affection, iron deficiency anemia, hemolytic anemia, hemoglobinopathies, and drug consumption. Aim To assess the role of HbA1c in the follow-up and control of Diabetes Mellitus across different patient populations and clinical scenarios. Methodology A quantitative research design to investigate the impact of residence location (inside or outside the Saudi Arabia). Through an electronic questionnaire in English and translated into Arabic, it was published online using Google Forms (Google, Mountain View, California) and was divided into three sections. Results The number of participating patients was 412 diabetic patients; their average age was from 51 to 60 years, and most of them were male. The study found a high level of awareness among diabetics about the HbA1c test, their knowledge of its importance, and their ability to perform the analysis regularly and periodically every year. However, there is a lack of practice, as most participants only performed follow-up every more than a few months, and the value of the last HbA1c test ranged between seven and ten. The percentage of diabetic patients whose cumulative blood sugar was more than ten and who did not take any action after learning of their high percentage (35.7%). Conclusion Diabetes is one of the most common health problems that continue to spread worldwide. HbA1c testing may continue to be implemented as an essential part of the diagnostic and prognostic tool, resulting in better patient care and successful clinical outcomes. Testing for glycosylated hemoglobin levels should be done every three months. Patients and doctors should be cautioned not to rely exclusively on two-hour post-prandial blood glucose results, particularly in the case of insulin-dependent diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.